Outcomes of Treatment for Glioblastoma Multiforme in Adult Patients: A Single Institution Experience from the Eastern Black Sea Region of Turkey


KANDAZ M. , BAHAT Z. , Guler O. C. , CANYILMAZ E. , YAZAR U. , Yoney A.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, cilt.28, ss.30-35, 2018 (SCI İndekslerine Giren Dergi) identifier identifier

  • Cilt numarası: 28 Konu: 1
  • Basım Tarihi: 2018
  • Doi Numarası: 10.4999/uhod.182195
  • Dergi Adı: UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
  • Sayfa Sayıları: ss.30-35

Özet

The aim of the present study was to observe the relationship between age distribution and overall survival in glioblastoma multiforme. A series of 274 glioblastoma patients were analyzed retrospectively. Patients received chemoradiation with temozolomide. For the whole population, median overall survival time was 9.80 +/- 1.78 (95% CI, 6.31-13.28) months and 1-, 2- and 3-years survival rates were 38.3%, 16.1% and 8.4% respectively. Median survival time of the patients <= 5th, 6th, 7th and >= 8th decade 26.00 +/- 7.12, 14.42 +/- 3.07, 13.65 +/- 2.14 and 5.25 +/- 0.73 respectively. There were a statistically significant difference in median survival rates among the four groups (p < 0.001). GBM remains a poor prognosis and fatal brain tumor despite the availability of multimodal treatment options. Age can be considered as the most important prognostic factor in patients with GBM as elderly patients have an extremely poor prognosis. Further research is thus warranted for the selection of treatment options that can improve the OS as well as ensure quality of life in the adult patients.